Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5078725 | 0.93 | APEX1 (0.34) | SMN1; SMN2APEX1PGRCYP1A2CYP2C19 | |
| SCHEMBL5078657 | 0.92 | CYP2C9 (0.33) | SMN1; SMN2CYP2C19KMT2A | |
| SCHEMBL5081723 | 0.90 | PDK2 (0.33) | CYP2C19 | |
| SCHEMBL5082314 | 0.88 | SMN1; SMN2 (0.33) | SMN1; SMN2APEX1CYP1A2CYP2C19KMT2A | |
| SCHEMBL5084660 | 0.87 | ALDH1A1 (0.33) | APEX1PGRCYP1A2CYP2C19KMT2A | |
| SCHEMBL5085328 | 0.87 | ALDH1A1 (0.33) | SMN1; SMN2APEX1ALDH1A1 | |
| SCHEMBL5078695 | 0.85 | SMN1; SMN2 (0.34) | SMN1; SMN2APEX1CYP1A2CYP2C19KMT2A | |
| SCHEMBL5082307 | 0.84 | CYP2C19 (0.36) | SMN1; SMN2APEX1PGRCYP1A2CYP2C19 | |
| SCHEMBL5081808 | 0.83 | SMN1; SMN2 (0.33) | SMN1; SMN2APEX1CYP1A2KMT2AALDH1A1 | |
| SCHEMBL6437219 | 0.83 | APEX1 (0.40) | SMN1; SMN2APEX1PGRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142146-A1 | Catalyst for olefin polymerization and use of the same | CHINA PETROLEUM & CHEMICAL CORPORATION | 2006-06-29 | — | — | US | claimed |
| US-6822109-B2 | TRIHYDROCARBYLSILYLATION; ADDITION POLYMERIZATION OF OLEFINS | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2004-11-23 | — | — | US | claimed |
| US-20040106814-A1 | Silicon ether compound, a method for the preparation thereof and use thereof | BEIJING RESEARCH INSTITUTE OF CHEMICAL INDUSTRY, CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2004-06-03 | — | — | US | claimed |
| US-7323431-B2 | Catalyst for olefin polymerization and use of the same | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2008-01-29 | — | — | US | disclosed |
| US-20060142146-A1 | Catalyst for olefin polymerization and use of the same | CHINA PETROLEUM & CHEMICAL CORPORATION | 2006-06-29 | — | — | US | disclosed |
| US-6822109-B2 | TRIHYDROCARBYLSILYLATION; ADDITION POLYMERIZATION OF OLEFINS | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2004-11-23 | — | — | US | disclosed |
| US-20040106814-A1 | Silicon ether compound, a method for the preparation thereof and use thereof | BEIJING RESEARCH INSTITUTE OF CHEMICAL INDUSTRY, CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106814-A1 | Silicon ether compound, a method for the preparation thereof and use thereof | SIK1, CDK20, SGMS1 | SMN1; SMN2 2860/4885APEX1 1975/4885PGR 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.